WO2009155488A3 - Nouveau sel oxalate et nouveau cristal de o-desméthylvenlafaxine - Google Patents

Nouveau sel oxalate et nouveau cristal de o-desméthylvenlafaxine Download PDF

Info

Publication number
WO2009155488A3
WO2009155488A3 PCT/US2009/047907 US2009047907W WO2009155488A3 WO 2009155488 A3 WO2009155488 A3 WO 2009155488A3 US 2009047907 W US2009047907 W US 2009047907W WO 2009155488 A3 WO2009155488 A3 WO 2009155488A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystal
desmethylvenlafaxine
salt
oxalate salt
novel
Prior art date
Application number
PCT/US2009/047907
Other languages
English (en)
Other versions
WO2009155488A2 (fr
Inventor
Dario Braga
Stefano Luca Giaffreda
Marco Curzi
Original Assignee
Segrub, Llc
Polycrystalline, S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Segrub, Llc, Polycrystalline, S.R.L. filed Critical Segrub, Llc
Publication of WO2009155488A2 publication Critical patent/WO2009155488A2/fr
Publication of WO2009155488A3 publication Critical patent/WO2009155488A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne un nouveau sel et un nouveau cristal de l'ingrédient pharmaceutique actif, O-Desméthylvenlafaxine, et concerne des procédés de préparation du sel et du cristal, des compositions pharmaceutiques comprenant le sel et le cristal ainsi que des méthodes de traitement d'un patient avec le sel et le cristal.
PCT/US2009/047907 2008-06-19 2009-06-19 Nouveau sel oxalate et nouveau cristal de o-desméthylvenlafaxine WO2009155488A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7404108P 2008-06-19 2008-06-19
US61/074,041 2008-06-19
US11340908P 2008-11-11 2008-11-11
US61/113,409 2008-11-11

Publications (2)

Publication Number Publication Date
WO2009155488A2 WO2009155488A2 (fr) 2009-12-23
WO2009155488A3 true WO2009155488A3 (fr) 2010-04-08

Family

ID=41434703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/047907 WO2009155488A2 (fr) 2008-06-19 2009-06-19 Nouveau sel oxalate et nouveau cristal de o-desméthylvenlafaxine

Country Status (1)

Country Link
WO (1) WO2009155488A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ200969A3 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
EP3544603A2 (fr) * 2016-11-23 2019-10-02 Bohne Askøy AS Prévention et/ou traitement du syndrome de fatigue

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103603A2 (fr) * 2002-06-10 2003-12-18 Wyeth Nouveau sel de type formiate de o-desmethylvenlafaxine
US20070053968A1 (en) * 2005-09-07 2007-03-08 Wyeth Transdermal drug delivery devices containing O-Desmethyl Venlafaxine (ODV) or its salts
US20070054964A1 (en) * 2005-09-07 2007-03-08 Wyeth Topical formulations containing O-Desmethyl Venlafaxine (ODV) or its salts
US20070110808A1 (en) * 2003-06-05 2007-05-17 Alembic Limited Extended release osmo-microsealed formulation
WO2010008735A2 (fr) * 2008-06-16 2010-01-21 Teva Pharmaceutical Industries Ltd. États solides de sels de o-desméthylvenlafaxine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103603A2 (fr) * 2002-06-10 2003-12-18 Wyeth Nouveau sel de type formiate de o-desmethylvenlafaxine
US20070110808A1 (en) * 2003-06-05 2007-05-17 Alembic Limited Extended release osmo-microsealed formulation
US20070053968A1 (en) * 2005-09-07 2007-03-08 Wyeth Transdermal drug delivery devices containing O-Desmethyl Venlafaxine (ODV) or its salts
US20070054964A1 (en) * 2005-09-07 2007-03-08 Wyeth Topical formulations containing O-Desmethyl Venlafaxine (ODV) or its salts
WO2010008735A2 (fr) * 2008-06-16 2010-01-21 Teva Pharmaceutical Industries Ltd. États solides de sels de o-desméthylvenlafaxine

Also Published As

Publication number Publication date
WO2009155488A2 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
WO2012051318A8 (fr) Composés sulfonamides et leurs procédés de fabrication et d'utilisation
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
WO2009152356A3 (fr) Composés et compositions utiles pour le traitement de la malaria
WO2008132229A3 (fr) Solutions et compositions hautement concentrées en insuline
IL194850A (en) Benzoazepine-oxy-acetic acid derivatives used as delta-ppar agonists for raising c-hdl levels, lowering c-ldl levels, and lowering cholesterol levels and their pharmacological compounds
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2009024611A3 (fr) 4-benzylaminoquinoléines, compositions pharmaceutiques les contenant, et leur utilisation en thérapie
WO2011012816A3 (fr) Formulation pharmaceutique
WO2010118291A3 (fr) Modulateurs à base d'acide biphényl-3-carboxylique du béta-3-adrénorécepteur
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2007125105A3 (fr) Activateurs de la glucokinase benzamidique
WO2010147830A3 (fr) Modulateurs aminothiazole de bêta-3-adrénorécepteur
WO2011017502A3 (fr) Formulations comprenant du linaclotide
WO2010055082A3 (fr) Nouvelle forme cristalline de malate de sunitinib
WO2008079610A3 (fr) Nouveaux inhibiteurs d'acétyl-coa-carboxylase (acc) et utilisation dans le traitement du diabète, de l'obésité et du syndrome métabolique
WO2010054757A8 (fr) Combinaisons d'agents actifs présentant des propriétés insecticides et acaricides
WO2012049307A3 (fr) Nouveaux dérivés d'insuline à extrémité n modifiée
WO2011144983A3 (fr) Procédé amélioré pour la préparation de lacosamide
WO2009060952A1 (fr) Nouvelle préparation
WO2010056527A3 (fr) Composés hétérocycliques condensés en tant que modulateurs de canaux ioniques
WO2009050197A3 (fr) Composés organiques
WO2008092219A3 (fr) Composition pharmaceutique comprenant du tramadol et du cétoprofène en association

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09767797

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09767797

Country of ref document: EP

Kind code of ref document: A2